Study of Secukinumab With 2 mL Pre-filled Syringes

NCT02748863 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Placebo
DRUG: Secukinumab 2 mL form
DRUG: Secukinumab 1 mL form

Sponsor

Novartis Pharmaceuticals